Table 1

Effect of physiological (low dose, 0.4 pmol/kg/min) and supraphysiological (high dose, 1.2 pmol/kg/min) doses of GLP-1 on plasma glucose, and plasma immunoreactivities of GLP-1, insulin, glucagon, and pancreatic polypeptide with intraduodenal perfusion of saline or lipid (2.5 kcal/min, 2.5 ml/min)

GLP-1
(pmol/l•60 min) 		Plasma glucose (mmol/l•60 min) Insulin
(mU/l•60 min) 		Glucagon (pg/ml•60 min) Pancreatic polypeptide (pg/ml•60 min)
Intraduodenal saline
Saline iv−0.8  (1.0)0.3  (0.1)1.5  (1.7)22.4  (16.2)10.8  (29.7)
 GLP-1 iv: low dose25.2 (2.6)1-150 −2.3 (0.3)1-150 11.3 (2.4)1-150 −59.0 (37.1)1-150 −90.5 (32.7)1-150
 GLP-1 iv: high dose67.4 (4.0)1-150 1-152 −2.5 (0.4)1-150 11.9 (5.1)1-150 −68.6 (28.9)1-150 −128.9 (33.2)1-150
Intraduodenal lipid
Saline iv7.5 (1.7)1-151 −1.2 (0.3)1-151 25.5 (4.4)1-151 145.9 (21.6)1-151 289.5 (66.9)1-151
 GLP-1 iv: low dose33.8 (2.9)1-150 1-151 −4.7 (0.5)1-150 1-151 24.7 (4.8)1-151 99.7 (25.1)1-150 1-151 7.7 (55.4)1-150 1-151
 GLP-1 iv: high dose75.2 (3.9)1-150 1-152 1-151 −4.5 (0.7)1-150 1-151 31.4 (8.3)1-151 48.0 (33.8)1-150 1-152 1-151 −104.2 (71.1)1-150 1-152
 Saline iv: recovery17.1 (3.1)1-150 1-152 1-153 −0.8 (0.6)1-152 1-153 18.3 (2.7)189.0 (44.7)1-152 1-153 294.4 (93.0)1-152 1-153

  • Mean (SEM) of AUC over basal during each 60 minute infusion period; n=11.

  • For the same intraduodenal perfusion:

  • ↵1-150 p<0.05v saline iv;

  • ↵1-152 p<0.05v low dose GLP-1;

  • ↵1-153 p<0.05v high dose GLP-1. For different intraduodenal perfusions:

  • ↵1-151 p<0.05 v the same intravenous infusion/intraduodenal saline.